Evidence map›Paper›PMID 30963090›Full record

ArticleInternational journal of cardiology. Heart & vasculature2019

Hospitalization cost reduction with sacubitril-valsartan implementation in a cohort of patients from the Daunia Heart Failure Registry.

Michele Correale, Ilenia Monaco, Armando Ferraretti, Lucia Tricarico, Giuseppina Padovano, Ennio Sascia Formica, Valeria Tozzi, Davide Grazioli, Matteo Di Biase, Natale Daniele Brunetti

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of cardiology. Heart & vasculature, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Sacubitril/valsartan in HFrEF - Should the aces up our sleeves be played earlier?International journal of cardiology. Heart & vasculature · 2019
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Michele CorrealeDepartment of Medical & Surgical Sciences, University of Foggia, Italy.
Ilenia MonacoDepartment of Medical & Surgical Sciences, University of Foggia, Italy.
Armando FerrarettiDepartment of Medical & Surgical Sciences, University of Foggia, Italy.
Lucia TricaricoDepartment of Medical & Surgical Sciences, University of Foggia, Italy.
Giuseppina PadovanoDepartment of Medical & Surgical Sciences, University of Foggia, Italy.
Ennio Sascia FormicaDepartment of Medical & Surgical Sciences, University of Foggia, Italy.
Valeria TozziDepartment of Medical & Surgical Sciences, University of Foggia, Italy.
Davide GrazioliCardio-Thoracic Department, Ospedali Riuniti University Hospital, Foggia, Italy.
Matteo Di BiaseGVM Care & Research, Santa Maria Hospital, Bari, Italy.
Natale Daniele BrunettiDepartment of Medical & Surgical Sciences, University of Foggia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAim of this study was to assess the impact of the introduction of new class of drugs (ARNI: angiotensin receptor-neprilysin inhibitor) on hospital related costs in a real world cohort of patients with chronic heart failure (CHF).

methodsSeventy-three consecutive patients with CHF and systolic dysfunction eligible for the treatment with ARNIs from the Daunia Heart Failure Registry were enrolled. Incidence of hospitalizations before and after treatment with ARNI, costs for drug and hospitalization for HF were recorded, indexed per year and compared.

resultsIndexed mean number of hospitalizations per year was 0.93 ± 1.70 before and 0.19 ± 0.70 after introduction of ARNI (

conclusionIn a real world scenario, treatment with ARNI is associated with lower indexed rates of hospitalizations and hospitalization related costs. Cost reduction increases with at least one indexed hospitalization for heart failure before treatment with ARNI.

Indexed as

Angiotensin receptor blockersARNIChronic heart failureCost analysisNeprilysin inhibitionSacubitril

Identifiers

PMID30963090
PMCPMC6437279

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.